Coenzyme Q10 / ubiquinol
Mechanism, regulatory status, and an honest, tiered evidence map.
What it is
Class: Electron carrier / antioxidant
Also known as: CoQ10, ubiquinone, ubiquinol
Relationship to mitochondrial health: Coenzyme Q10 is an endogenous mobile electron carrier of the respiratory chain and a lipid-phase antioxidant. Supplementation is a repletion strategy; its strongest human evidence is a mortality trial in a heart-failure DISEASE population, not a healthy-aging study.
Regulatory status
Sold as a dietary supplement; not an approved drug for aging. The Q-SYMBIO evidence is in chronic heart failure — a disease-treatment context — and does NOT constitute an aging or longevity indication.
Mechanism
Component of OXPHOS electron transport; the Q-SYMBIO RCT measured major adverse cardiovascular events and mortality in chronic heart-failure patients. See /cellular-respiration-oxphos.
Evidence — Human (randomized, disease population)
| Species / population | Adults with chronic (NYHA class III-IV) heart failure (Q-SYMBIO, Mortensen 2014, n=420). |
| Exposure, route, schedule | Oral CoQ10 100 mg three times daily on top of standard heart-failure therapy. |
| Comparator / duration | Placebo-controlled, randomized, double-blind; ~2-year follow-up. |
| Endpoint / numeric result | Lower major adverse cardiovascular events and lower all-cause mortality vs placebo in the heart-failure population. |
| What it did NOT establish | This is disease treatment in heart-failure patients — it is NOT evidence of a healthy-aging, longevity, or lifespan-extension benefit in the general population. |
Negative or null findings
- CoQ10 supplementation has not shown a healthy-aging or lifespan benefit in a general (non-disease) population.
- Statin-related myalgia and other proposed uses have weaker/mixed evidence and are outside this mortality-outcome result.